Prevention and treatment of gerbil hepatitis E using the programmable CRISPR-Cas13d system  

作　　者：Chengcheng Zhao Chong Lia Sa Li Hanyu Wu Pengyao Ren Tianlong Liu Xiaoxiang Hu Ran Zhang 

机构地区：[1]State Key Laboratory of Animal Biotech Breeding,College of Biological Sciences,China Agricultural University,Beijing 100193,China [2]Laboratory of Veterinary Pathology and Nanopathology,College of Veterinary Medicine,China Agricultural University,Beijing 100193,China

出　　处：《Genes & Diseases》2024年第4期94-97,共4页基因与疾病（英文）

基　　金：supported by the National Transgenic Major Program of China(No.2016ZX08009-003-006);Plan 111(No.B12008).

摘　　要：In recent years,the global incidence of hepatitis E virus(HEV)has been rising,leading to increased morbidity and mortality associated with hepatitis.Cas13,a CRISPR effector,shows promise as an antiviral agent against singlestranded RNA viruses.Cas13d,a type VI-D effector,exhibits higher efficiency in suppressing RNA viruses compared to other type VI variants.However,its in vivo activity against RNA viruses in mammals remains unknown.

关 键 词：MORTALITY HEPATITIS treatment 

分 类 号：R512.6[医药卫生—内科学]